Literature DB >> 18695886

BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.

Xiaoping Yu1, Yuanqiong Luo, Yong Zhou, Qianyong Zhang, Jian Wang, Na Wei, Mantian Mi, Jundong Zhu, Bin Wang, Hui Chang, Yong Tang.   

Abstract

It is well established that statins display potent anticancer activity in several types of proliferating tumor cells. However, how to promote the sensitivity of statins to mammary cancer is yet to be completely deciphered. The purpose of this study was to investigate whether breast cancer susceptibility gene 1 (BRCA1) overexpression sensitizes mammary cancer cells to statins. MCF-7 cells, which have only one wild-type BRCA1 allele, were transfected with pcDNA3-beta-HA-hsBRCA1 plasmids via liposomes to reconstitute BRCA1 overexpression human breast cancer cell line, and tumoral xenografts with BRCA1 overexpression were subsequently established in BALB/c nude mice. Then, the inhibitory activity of lovastatin on cancer cells and tumoral xenografts, and the underlying mechanism involving in cell-cycle regulatory proteins were analyzed. The proliferative ability of MCF-7 cells treated with lovastatin was reduced compared to normal, and further decreased in the presence of excess BRCA1, detected by methyl thiazolyl tetrazolium and flow cytometry techniques in vitro or by 5-bromodeoxyuridine incorporation in vivo. Additionally, the mRNA and protein expression of cyclin D1, cyclin-dependent kinase 4 (CDK4) and retinoblastoma protein (pRb), was further down-regulated under exposure to lovastatin in condition of BRCA1 overexpression, but the expression of p21WAF1/CIP1, a cyclin-dependent kinase inhibitor (CDKI), was further up-regulated, both in vitro and in vivo detected with quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis. Moreover, we found the further reduced volume of tumoral xenografts treated with lovastatin in the presence of BRCA1 overexpression. Our results suggest that BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway, which will provide an innovative experimental framework to study control of breast cancer cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695886

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

Review 1.  The effect of statins on cancer cells--review.

Authors:  Lucyna Matusewicz; Justyna Meissner; Monika Toporkiewicz; Aleksander F Sikorski
Journal:  Tumour Biol       Date:  2015-05-23

2.  Controversial BRCA1 allelotypes in commonly used breast cancer cell lines.

Authors:  Sivasundaram Karnan; Morassa Mohseni; Yuko Konishi; Akina Tamaki; Yoshitaka Hosokawa; Ben H Park; Hiroyuki Konishi
Journal:  Breast Cancer Res Treat       Date:  2009-07-08       Impact factor: 4.872

Review 3.  Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.

Authors:  Naomi Gronich; Gad Rennert
Journal:  Nat Rev Clin Oncol       Date:  2013-10-01       Impact factor: 66.675

4.  Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.

Authors:  Monica N Schointuch; Timothy P Gilliam; Jessica E Stine; Xiaoyun Han; Chunxiao Zhou; Paola A Gehrig; Kenneth Kim; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2014-05-28       Impact factor: 5.482

5.  Elevated expression of CDK4 in lung cancer.

Authors:  Aibing Wu; Bin Wu; Jinsong Guo; Weiren Luo; Dong Wu; Huiling Yang; Yan Zhen; Xiaoli Yu; Hao Wang; Ying Zhou; Zhen Liu; Weiyi Fang; Zhixiong Yang
Journal:  J Transl Med       Date:  2011-04-11       Impact factor: 5.531

6.  Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.

Authors:  Heidrun Karlic; Roman Thaler; Christopher Gerner; Thomas Grunt; Katharina Proestling; Florian Haider; Franz Varga
Journal:  Cancer Genet       Date:  2015-03-18

Review 7.  Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.

Authors:  Christian Henninger; Gerhard Fritz
Journal:  Cell Death Dis       Date:  2017-01-19       Impact factor: 8.469

Review 8.  Thymidine analogues for tracking DNA synthesis.

Authors:  Brenton L Cavanagh; Tom Walker; Anwar Norazit; Adrian C B Meedeniya
Journal:  Molecules       Date:  2011-09-15       Impact factor: 4.411

9.  Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins.

Authors:  Chanjuan Zheng; Shichao Yan; Lu Lu; Hui Yao; Guangchun He; Sisi Chen; Ying Li; Xiaojun Peng; Zhongyi Cheng; Mi Wu; Qiuting Zhang; Guifei Li; Shujun Fu; Xiyun Deng
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

10.  The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.

Authors:  Jessica E Stine; Hui Guo; Xiugui Sheng; Xiaoyun Han; Monica N Schointuch; Timothy P Gilliam; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Oncotarget       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.